Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in million yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company recorded ¥89.900 million in net sales from raw materials sales and ¥84.598 million from a review of the profit-sharing method following a contract amendment. It recorded a loss before income taxes and other adjustments due to research and development spending associated with advancing research and development activities, among other factors.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | 174 million yen (YoY +60.8%) |
| Operating profit | -965 million yen |
| Ordinary income | -866 million yen |
| Profit attributable to owners of the parent | -943 million yen |
| Net income per share | −¥12.90 |
| Operating Margin | -553.6 |
| Equity ratio | End of the current fiscal period 59.9 / End of previous period 68.2 |
| Total assets | 5,906 million yen |
| Net assets | 3,565 million yen |
| Cash flows from operating activities | -816 million yen |
| Cash flows from investing activities | 2,261 million yen |
| Cash flows from financing activities | 2,222 million yen |
| Cash and cash equivalents at end of period | 4,910 million yen |
| Annual Dividend Forecast | 0 yen → 0 yen（0.0%） |
| Depreciation and amortization | 497 thousand yen |
| Impairment loss | 19,790 thousand yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on disposal and sale of non-current assets 0 thousand yen, Impairment Losses 19,790 thousand yen, Loss on redemption of convertible bonds 54,024 thousand yen, Total extraordinary loss 73,814 thousand yen |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | Effective 1 April 2026, the company transitioned to a holding company structure through a company split and transferred its drug discovery business to the newly established NANO MRNA Co., Ltd. It also resolved that NANO MRNA Co., Ltd. would underwrite a third-party allotment of new shares by Luna RD Co., Ltd., making Luna RD Co., Ltd. a subsidiary with a voting rights ownership ratio of 66.67%. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 82,100,758 |
| Treasury Shares at Period-End | 32,329 |
| Factors Behind Changes in Business Performance | The company recorded ¥89.900 million in net sales from raw materials sales and ¥84.598 million from a review of the profit-sharing method following a contract amendment. It recorded a loss before income taxes and other adjustments due to research and development spending associated with advancing research and development activities, among other factors. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company recorded ¥89.900 million in net sales from raw materials sales and ¥84.598 million from a review of the profit-sharing method following a contract amendment. The losses were attributed in part to research and development spending associated with advancing research and development activities. The company also stated that it is difficult to calculate a reasonable earnings forecast because its investment business is significantly affected by the number of investments and stock market conditions, among other factors.